Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

Equity Bottom-Up

<p>We listened to <a href="https://www.smartkarma.com/entities/23716" target="_blank" data-smartkarma-citation="entities:23716:1">Cerecor Inc (CERC US)</a> management's conference call (<a href="http://ir.cerecor.com/ir-calendar/detail/756/topline-phase-2-results-for-cerc-301s-phase-2-trial-in" target="_blank">link</a>) about the phase 2 results of CERC-301 as adjunct therapy in major depressive disorder, MDD (<a href="http://ir.cerecor.com/press-releases/detail/30/cerecor-reports-top-line-data-from-cerc-301-phase-2-study" target="_blank">link to press release</a>). On closely analyzing the study data, we agree with the management's assessment that the antidepressant effect of the drug is more prominent at day 2 after oral administration and wears off slightly by day 4. We also agree that in future planned studies, the 20 mg dose of the drug may need to be given twice…</p>

We listened to Cerecor Inc (CERC US) management's conference call (link) about the phase 2 results of CERC-301 as adjunct therapy in major depressive disorder, MDD (link to press release). On closely analyzing the study data, we agree with the management's assessment that the antidepressant effect of the drug is more prominent at day 2 after oral administration and wears off slightly by day 4. We also agree that in future planned studies, the 20 mg dose of the drug may need to be given twice…

Cerecor's Novel Drugs for Major Depression. 'Failed' Trial or Buying Opportunity in the Stock?

United States

Cerecor Inc. is a clinical-stage biopharmaceutical company. The Company develops drugs for patients with neurological and psychiatric disorders. Cerecor conducts business in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cerecor's Novel Drugs for Major Depression. 'Failed' Trial or Buying Opportunity in the Stock?

We listened to Cerecor Inc (CERC US) management's conference call (link) about the phase 2 results of CERC-301 as adjunct therapy in major...

Dr. Bhavneesh Sharma, MD, MBA